The 'omics' revolution: Redefining the understanding and treatment of allergic skin diseases

Current Opinion in Allergy and Clinical Immunology

Volumn 16, Issue 5, 2016, Pages 469-476

  Oliva, Margeaux ^a   Renert Yuval, Yael ^a,b,c   Guttman Yassky, Emma ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Allergic contact dermatitis; atopic dermatitis; genomics; inflammatory; proteomics; transcriptomics

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ATOPIC DERMATITIS; DISEASE PREDISPOSITION; GENOMICS; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SKIN ALLERGY; SKIN INFECTION; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL; TRANSCRIPTOMICS; ANIMAL; GENE EXPRESSION PROFILING; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; SKIN DISEASES; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; HYPERSENSITIVITY; INTERLEUKINS; MOLECULAR TARGETED THERAPY; PROTEOMICS; SIGNAL TRANSDUCTION; SKIN DISEASES; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 84982796275     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000306     Document Type: Review

References (95)

1. Chiricozzi A, Saraceno R, Chimenti MS, et al. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets 2014; 18:513-525.
2. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-1847.
3. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013; 22:993-1005.
4. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 2015; 64:66-73.
5. Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013; 34:174-181.
6. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371:130-139.
7. Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014; 134:1293-1300.
8. Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy 2015; 7:1043-1058.
9. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 2015; 135:324-336.
10. Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 2014; 134:800-807.
11. Belsito DV. Patch testing: after 100 years, still the gold standard in diagnosing cutaneous delayed-type hypersensitivity. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1997; 195-202.
12. Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387:40-52.
13. Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 2014; 133:1626-1634.
14. Tintle S, Shemer A, Suarez-Farinas M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011; 128:583-593.e1-4.
15. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med 2015; 4:858-873.
16. Suarez-Farinas M, Ungar B, Correa da Rosa J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 2015; 135:1218-1227.
17. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352:2314-2324.
18. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part I: Clinical and pathologic concepts. J Allergy Clin Immunol 2011; 127:1110-1118.
19. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112 (6 Suppl):S118-S127.
20. Cole C, Kroboth K, Schurch NJ, et al. Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis. J Allergy Clin Immunol 2014; 134:82-91.
21. Esaki H, Ewald DA, Ungar B, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol 2015; 135:153-163.
22. Ewald DA, Malajian D, Krueger JG, et al. Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways. BMC Med Genomics 2015; 8:60.
23. Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012; 130:1344-1354.
24. Suarez-Farinas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011; 127:954-964.e1-4.
25. Tian S, Krueger JG, Li K, Jabbari A, et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the 'core' pathogenesis of disease. PLoS One 2012; 7:e44274.
26. Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract 2014; 2:371-379; quiz 80-1.
27. Danso MO, van Drongelen V, Mulder A, et al. TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol 2014; 134:1941-1950.
28. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008; 126:332-337.
29. Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing 'T22' T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009; 123:1244-1252.e2.
30. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 178:2229-2240.
31. Rabenhorst A, Hartmann K. Interleukin-31: a novel diagnostic marker of allergic diseases. Curr Allergy Asthma Rep 2014; 14:423.
32. Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 2013; 13:549-561.
33. Szegedi K, Kremer AE, Kezic S, et al. Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol 2012; 21:431-436.
34. Thepen T, Langeveld-Wildschut EG, Bihari IC, et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 1996; 97:828-837.
35. Dhingra N, Guttman-Yassky E. A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis. J Invest Dermatol 2014; 134:2071-2074.
36. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159:1092-1102.
37. Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 2012; 21:104-110.
38. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2015; 73:311-318.
39. Kezic S, O'Regan GM, Lutter R, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol 2012; 129:1031-1039.e1.
40. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365:1315-1327.
41. Margolis DJ, Apter AJ, Gupta J, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol 2012; 130:912-917.
42. Akdis CA, Akdis M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin Exp Allergy 2003; 33:1618-1621.
43. Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol 2013; 132:361-370.
44. Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(\+) TH2/TH1 cell imbalance, whereas adults acquire CLA(\+) TH22/TC22 cell subsets. J Allergy Clin Immunol 2015; 136:941-951.e3.
45. Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 2015; 136:1254-1264.
46. Winget J, Finlay D, Mills KJ, et al. Quantitative proteomic analysis of stratum corneum dysfunction in adult chronic atopic dermatitis. J Invest Dermatol 2016. [Epub ahead of print]
47. Li S, Ganguli-Indra G, Indra AK. Lipidomic analysis of epidermal lipids: a tool to predict progression of inflammatory skin disease in humans. Expert Rev Proteomics 2016; 13:451-456.
48. Broccardo CJ, Mahaffey S, Schwarz J, et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J Allergy Clin Immunol 2011; 127:186-193; 93.e1-11.
49. Sakabe J, Kamiya K, Yamaguchi H, et al. Proteome analysis of stratum corneum from atopic dermatitis patients by hybrid quadrupole-orbitrap mass spectrometer. J Allergy Clin Immunol 2014; 134:957-960.e8.
50. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151-1160.
51. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis.Eur J Immunol 2006; 36:1309-1323.
52. Hijnen D, De Bruin-Weller M, Oosting B, et al. Serum thymus and activationregulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113:334-340.
53. Shinkai A, Yoshisue H, Koike M, et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999; 163:1602-1610.
54. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120:150-155.
55. Brauweiler AM, Goleva E, Leung DY. Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol 2014; 134:2114-2121.
56. Kisich KO, Carspecken CW, Fieve S, et al. Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J Allergy Clin Immunol 2008; 122:62-68.
57. Niebuhr M, Scharonow H, Gathmann M, et al. Staphylococcal exotoxins are strong inducers of IL-22: a potential role in atopic dermatitis. J Allergy Clin Immunol 2010; 126:1176-1183.e4.
58. Nakamura Y, Oscherwitz J, Cease KB, et al. Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature 2013; 503:397-401.
59. Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 2010; 65:712-721.
60. Lehmann HS, Heaton T, Mallon D, Holt PG. Staphylococcal enterotoxin-Bmediated stimulation of interleukin-13 production as a potential aetiologic factor in eczema in infants. Int Arch Allergy Immunol 2004; 135:306-312.
61. Eyerich K, Pennino D, Scarponi C, et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009; 123:59-66.e4.
62. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-214.
63. Thomas CL, Fernandez-Penas P. The microbiome and atopic eczema: more than skin deep. Australas J Dermatol 2016. [Epub ahead of print]
64. Saeki H, Nakahara T, Tanaka A, et al. Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol 2016. [Epub ahead of print]
65. Cookson H, Smith C. Systemic treatment of adult atopic dermatitis. Clin Med 2012; 12:172-176.
66. Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30:729-747.
67. Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-tosevere psoriasis. J Allergy Clin Immunol 2014; 133:1032-1040.
68. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-1684.
69. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015; 136:116-124.e7.
70. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371:326-338.
71. Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep 2015; 1:25-26.
72. Fernandez-Anton Martinez MC, Alfageme Roldan F, Ciudad Blanco C, Suarez-Fernandez R. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 2014; 105:312-313.
73. Grzanka A, Zebracka-Gala J, Rachowska R, et al. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol 2012; 21:184-188.
74. Brunner PM, Khattri S, Garcet S, et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderateto-severe atopic dermatitis. J Allergy Clin Immunol 2016; 138:169-178.
75. Suarez-Farinas M, Gittler JK, Shemer A, et al. Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. J Allergy Clin Immunol 2013; 131:577-579.
76. Rozenblit M, Suarez-Farinas M, Shemer A, et al. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. J Allergy Clin Immunol 2014; 134:955-957.
77. Navarini AA, French LE, Hofbauer GF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011; 128:1128-1130.
78. Volf EM, Au SC, Dumont N, et al. A phase 2, open-label, investigator-initiated study to evaluate the safetyand efficacy ofapremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol 2012; 11:341-346.
79. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015; 73:395-399.
80. Kamsteeg M, Jansen PA, van Vlijmen-Willems IM, et al. Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. Br J Dermatol 2010; 162:568-578.
81. Camacho-Halili M, Axelrod S, Michelis MA, et al. A multicenter, retrospective review of patch testing for contact dermatitis in allergy practices. Ann Allergy Asthma Immunol 2011; 107:487-492.
82. Dhingra N, Shemer A, Correa da Rosa J, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol 2014; 134:362-372.
83. Newell L, Polak ME, Perera J, et al. Sensitization via healthy skin programs Th2 responses in individuals with atopic dermatitis. J Invest Dermatol 2013; 133:2372-2380.
84. Larsen JM, Bonefeld CM, Poulsen SS, et al. IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol 2009; 123:486-492.
85. Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol 2013; 131:300-313.
86. Novak N, Baurecht H, Schafer T, et al. Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol 2008; 128:1430-1435.
87. Fallon PG, Sasaki T, Sandilands A, et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet 2009; 41:602-608.
88. Siemund I, Hindsen M, Netterlid E, et al. Contact allergy in atopic individuals in relation to allergen-specific immunotherapy. Eur J Dermatol 2016; 26:271-280.
89. Correa da Rosa J, Malajian D, Shemer A, et al. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. J Allergy Clin Immunol 2015; 135:712-720.
90. Landeck L, Schalock P, Baden L, Gonzalez E. Contact sensitization pattern in 172 atopic subjects. Int J Dermatol 2011; 50:806-810.
91. Dhingra N, Gulati N, Guttman-Yassky E. Mechanisms of contact sensitization offer insights into the role of barrier defects vs. intrinsic immune abnormalities as drivers of atopic dermatitis. J Invest Dermatol 2013; 133:2311-2314.
92. Dietz L, Kinzebach S, Ohnesorge S, et al. Proteomic allergen-peptide/protein interaction assay for the identification of human skin sensitizers. Toxicol In Vitro 2013; 27:1157-1162.
93. Parkinson E, Boyd P, Aleksic M, et al. Stable isotope labeling method for the investigation of protein haptenation by electrophilic skin sensitizers. Toxicol Sci 2014; 142:239-249.
94. Vatti RR, Ali F, Teuber S, et al. Hypersensitivity reactions to corticosteroids. Clin Rev Allergy Immunol 2014; 47:26-37.
95. Han JS, Won KH, Chang SE, Kim JE. Tacrolimus 0.1% ointment in the treatment of allergic contact dermatitis: a new approach. Int J Dermatol 2014; 53:e470-e471.